Drug Search Results
More Filters [+]

Vanucizumab

Alternative Names: vanucizumab
Latest Update: 2023-05-03
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: VEGFA Blocker

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Vanucizumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Colorectal Cancer

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BP29889

P1

Completed

Oncology Solid Tumor Unspecified

2019-10-30

21%

BP29889

P1

Completed

Oncology Solid Tumor Unspecified

2019-10-30

21%

BP28179

P1

Completed

Oncology Solid Tumor Unspecified

2016-12-02

41%

McCAVE

P2

Terminated

Colorectal Cancer

2016-07-29

Recent News Events